Crolley, Valerie;
Bridgewater, John;
(2024)
Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements.
touchREVIEWS in Oncology & Haematology
, 20
(1)
pp. 12-19.
Preview |
Text
5.-touchONC_20.1_Crolley_12-19.pdf - Published Version Download (508kB) | Preview |
Abstract
Futibatinib is a selective fibroblast growth factor receptor (FGFR) inhibitor under investigation for use in cholangiocarcinoma (CCA), which is a rare but aggressive tumour of the bile ducts. There are limited treatment options for CCA, particularly in metastatic disease where outcomes are especially poor. This means that futibatinib could potentially be an important treatment option, particularly as it has good efficacy in patients resistant to treatment with other FGFR inhibitors. This article covers the history and status of futibatinib in the treatment of metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions and other rearrangements. The positive results from phase I and II clinical trials (including FOENIX-CCA2) have led to US Food and Drug Administration (FDA) approval of futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic iCCA with FGFR2 gene fusions or other rearrangements. Futibatinib has also been recommended for approval by the European Medicines Agency (EMA) and is being considered by the UK National Institute for Health and Care Excellence (NICE). However, primary and acquired resistance to futibatinib is still common, and a new generation of FGFR inhibitors may help to alleviate this issue. Phase III clinical trials in the first line (FOENIX-CCA3 and SAFIR-ABC-10) are either underway or due to start shortly, which will help to further clarify the position of futibatinib in the treatment paradigm of metastatic iCCA.
| Type: | Article |
|---|---|
| Title: | Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements |
| Open access status: | An open access version is available from UCL Discovery |
| Publisher version: | https://touchoncology.com/?p=104522 |
| Language: | English |
| Additional information: | This version is the version of record. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | Cancer, cholangiocarcinoma (CCA), fibroblast growth factor receptor (FGFR), fibroblast growth factor receptor 2 (FGFR2), futibatinib (Lytgobi®), infigratinib, intrahepatic cholangiocarcinoma, lirafugratinib , pemigatinib, RLY-4008, TAS-120, tinengotinib |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10193370 |
Archive Staff Only
 |
View Item |
